Teva pharmaceuticals v. sandoz: Availability of generic glatiramer acetate and the impact to patent litigation claim construction

0Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.

Abstract

In the upcoming case of Teva Pharmaceuticals v. Sandoz, the U.S. Supreme Court will address how much deference the appellate court should afford to a trial court's claim construction ruling. The effect of this decision will be far-reaching, as how claims are construed can determine whether a patent is infringed or not infringed, valid or invalid.

Cite

CITATION STYLE

APA

Fogel, L. E., & Ray, C. J. (2015, January 1). Teva pharmaceuticals v. sandoz: Availability of generic glatiramer acetate and the impact to patent litigation claim construction. Expert Opinion on Therapeutic Patents. Informa Healthcare. https://doi.org/10.1517/13543776.2014.977866

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free